Logo Logo
Hilfe
Kontakt
Switch language to English
Characterization of GAD-reaktive B cells and their B-cell receptor repertoire in the periphery and central nervous system
Characterization of GAD-reaktive B cells and their B-cell receptor repertoire in the periphery and central nervous system
Antibodies (abs) against the intracellular cytoplasmic protein glutamic acid decarboxylase 65 (GAD65) occur in different neurological disorders. Hereby, patients with anti-GAD65 ab associated autoimmune neurological disorders (GAD-AIND) exhibit high levels of anti-GAD65 abs in the serum as well as in the cerebrospinal fluid (CSF). However, the sites of immunological dysregulation and the triggers for the production of auto-abs against GAD65 are unclear. Furthermore, investigations on the pathogenic relevance of anti-GAD65 abs and their producing cells have yielded conflicting results. In consequence, the treatment of patients with GAD-AIND remains challenging. Therefore, investigating the functional properties of GAD-reactive B cells and anti-GAD65 abs could help to gain insights into the pathophysiology of GAD-AIND and assist the development of new treatment strategies. To this end, we analyzed GAD-reactive B cells in peripheral blood of patients with GAD-AIND as well as bone marrow (bm) cells of one patient. As a next step, we generated monoclonal patient-derived abs from peripheral blood (PB) and CSF cells and characterized their reactivity to GAD in different assays. Moreover, we analyzed the auto-abs for sequence specificities, e.g., subclass distribution, and somatic hypermutations (SHMs). In the first study, we could detect anti-GAD65 ab producing cells derived from GAD-reactive B cells in the peripheral blood (PB) of fifteen patients with GAD-AIND. Compared to our healthy control group consisting of nineteen donors, cells producing anti-GAD65 abs were highly elevated. Furthermore, we could identify bm plasma cells as an additional source of anti-GAD65 abs. The frequency of GAD-reactive B cells was comparable to B cells reactive for common recall antigens (ags) e.g. tetanus toxoid. In a second study, we included six patients with GAD-AIND and were able to generate 30 monoclonal abs (mabs) with 25 mabs derived from CSF cells and 5 mabs derived from PB cells. Mabs could be generated in patients with a short disease duration at the time of sampling. Thereby, we identified 10 GAD65-reactive mabs (CSF: 6/25; PB: 4/5) with enzyme-linked-immunosorbent-assay (ELISA). Furthermore, we could demonstrate that the intrathecal anti-GAD65 response is polyclonal and that the mabs had undergone affinity maturation when being compared to non-GAD65-reactive mabs. By reverting the SHMs of three GAD-reactive mabs to their germline sequences, we could show that affinity maturation is essential for the reactivity towards GAD65. Taken together, our data characterize the B cell response in the CSF of patients with GAD-AIND, showing that the anti-GAD65 response is polyclonal and affinity maturation is necessary for the recognition of GAD65. Additionally, we could for the first time proof that anti-GAD65-ab-producing cells are present in the central nervous system. In addition, our data support the clinical observation that a B-cell depleting therapy might not be suitable for the treatment of long-standing GAD-AIND.
GAD, Autoantibodies, B cells
Biljecki, Michelle
2022
Englisch
Universitätsbibliothek der Ludwig-Maximilians-Universität München
Biljecki, Michelle (2022): Characterization of GAD-reaktive B cells and their B-cell receptor repertoire in the periphery and central nervous system. Dissertation, LMU München: Graduate School of Systemic Neurosciences (GSN)
[thumbnail of Biljecki_Michelle.pdf]
Vorschau
PDF
Biljecki_Michelle.pdf

13MB

Abstract

Antibodies (abs) against the intracellular cytoplasmic protein glutamic acid decarboxylase 65 (GAD65) occur in different neurological disorders. Hereby, patients with anti-GAD65 ab associated autoimmune neurological disorders (GAD-AIND) exhibit high levels of anti-GAD65 abs in the serum as well as in the cerebrospinal fluid (CSF). However, the sites of immunological dysregulation and the triggers for the production of auto-abs against GAD65 are unclear. Furthermore, investigations on the pathogenic relevance of anti-GAD65 abs and their producing cells have yielded conflicting results. In consequence, the treatment of patients with GAD-AIND remains challenging. Therefore, investigating the functional properties of GAD-reactive B cells and anti-GAD65 abs could help to gain insights into the pathophysiology of GAD-AIND and assist the development of new treatment strategies. To this end, we analyzed GAD-reactive B cells in peripheral blood of patients with GAD-AIND as well as bone marrow (bm) cells of one patient. As a next step, we generated monoclonal patient-derived abs from peripheral blood (PB) and CSF cells and characterized their reactivity to GAD in different assays. Moreover, we analyzed the auto-abs for sequence specificities, e.g., subclass distribution, and somatic hypermutations (SHMs). In the first study, we could detect anti-GAD65 ab producing cells derived from GAD-reactive B cells in the peripheral blood (PB) of fifteen patients with GAD-AIND. Compared to our healthy control group consisting of nineteen donors, cells producing anti-GAD65 abs were highly elevated. Furthermore, we could identify bm plasma cells as an additional source of anti-GAD65 abs. The frequency of GAD-reactive B cells was comparable to B cells reactive for common recall antigens (ags) e.g. tetanus toxoid. In a second study, we included six patients with GAD-AIND and were able to generate 30 monoclonal abs (mabs) with 25 mabs derived from CSF cells and 5 mabs derived from PB cells. Mabs could be generated in patients with a short disease duration at the time of sampling. Thereby, we identified 10 GAD65-reactive mabs (CSF: 6/25; PB: 4/5) with enzyme-linked-immunosorbent-assay (ELISA). Furthermore, we could demonstrate that the intrathecal anti-GAD65 response is polyclonal and that the mabs had undergone affinity maturation when being compared to non-GAD65-reactive mabs. By reverting the SHMs of three GAD-reactive mabs to their germline sequences, we could show that affinity maturation is essential for the reactivity towards GAD65. Taken together, our data characterize the B cell response in the CSF of patients with GAD-AIND, showing that the anti-GAD65 response is polyclonal and affinity maturation is necessary for the recognition of GAD65. Additionally, we could for the first time proof that anti-GAD65-ab-producing cells are present in the central nervous system. In addition, our data support the clinical observation that a B-cell depleting therapy might not be suitable for the treatment of long-standing GAD-AIND.